GlassScriptPhysician profile
Sandeep K Dhillon
NPI 1245232941
$2,420.26
in general payments reported to CMS, 2019-2025
31 companies · $327 in 2025
The $327 reported for 2025 was more than what 86% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $115 · 2021: $311 · 2022: $402 · 2023: $570 · 2024: $528 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,425.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $735.85 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Biotech, INC. | $297.58 | 2023-2025 | Stelara, Tremfya |
| Medtronic, INC. | $236.49 | 2021-2022 | |
| Intra-Sana Laboratories | $140.68 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Asahi Intecc USA, INC. | $125.42 | 2023 | Asahi Ptca Guide Wire |
| Biohaven Pharmaceuticals, INC. | $99.77 | 2021 | |
| Novo Nordisk INC | $78.55 | 2022-2023 | |
| Lucid Diagnostics INC. | $74.58 | 2022 | |
| Glaxosmithkline, LLC. | $67.11 | 2021-2023 | Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.43 | 2021-2025 | Xifaxan |
| Neos Therapeutics, LP | $57.47 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $51.58 | 2019-2020 | |
| Ibsa Pharma INC. | $38.08 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.73 | 2020 | |
| Shire North American Group INC | $31.21 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $28.76 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $26.77 | 2023 | Abilify Asimtufii |
| Pfizer INC. | $23.50 | 2021 | |
| Impel Pharmaceuticals INC. | $20.87 | 2022 | |
| Dexcom, INC. | $20.72 | 2023 | Dexcom G6 Transmitter |
| Lundbeck LLC | $19.70 | 2022 | |
| Nestle Healthcare Nutrition INC. | $18.22 | 2021 | |
| Astellas Pharma US INC | $18.17 | 2024 | Veozah |
| Corcept Therapeutics | $17.92 | 2024 | Korlym |
| Kaleo, INC. | $15.75 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.23 | 2021 | |
| Esperion Therapeutics, INC. | $15.00 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.04 | 2019 | |
| Avion Pharmaceuticals | $13.89 | 2022 | |
| Biogen, INC. | $13.67 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.52 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Dhillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.